PRTC vs. GNS, ONT, ERGO, SLN, OXB, HZD, FARN, VRP, ARIX, and CIR
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry.
PureTech Health vs. Its Competitors
Genus (LON:GNS) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.
77.8% of Genus shares are held by institutional investors. Comparatively, 79.9% of PureTech Health shares are held by institutional investors. 0.8% of Genus shares are held by company insiders. Comparatively, 15.9% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Genus has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.
In the previous week, Genus had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Genus and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.75 beat Genus' score of 0.19 indicating that PureTech Health is being referred to more favorably in the news media.
Genus has a net margin of 1.18% compared to PureTech Health's net margin of -17,620.94%. Genus' return on equity of 1.41% beat PureTech Health's return on equity.
Genus currently has a consensus target price of GBX 2,150, indicating a potential downside of 3.85%. PureTech Health has a consensus target price of GBX 455, indicating a potential upside of 242.11%. Given PureTech Health's higher probable upside, analysts plainly believe PureTech Health is more favorable than Genus.
Genus has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Summary
Genus beats PureTech Health on 9 of the 15 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
This page (LON:PRTC) was last updated on 7/15/2025 by MarketBeat.com Staff
Free PRTC Stock Alerts